DBV Technologies (NASDAQ:DBVT) Stock Price Down 6.9% – Here’s Why

Shares of DBV Technologies S.A. (NASDAQ:DBVT) were down 6.9% during mid-day trading on Wednesday . The stock traded as low as $16.30 and last traded at $16.15. Approximately 49,508 shares changed hands during trading, a decline of 83% from the average session volume of 296,577 shares. The stock had previously closed at $17.35.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. Weiss Ratings restated a “sell (d-)” rating on shares of DBV Technologies in a research note on Monday, June 29th. Citigroup reissued an “outperform” rating on shares of DBV Technologies in a report on Friday, May 1st. HC Wainwright restated a “buy” rating on shares of DBV Technologies in a research report on Tuesday, June 30th. Guggenheim reaffirmed a “buy” rating and issued a $51.00 price target on shares of DBV Technologies in a report on Monday, May 4th. Finally, Wall Street Zen downgraded shares of DBV Technologies from a “hold” rating to a “sell” rating in a research report on Saturday, July 4th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, DBV Technologies currently has a consensus rating of “Moderate Buy” and a consensus target price of $48.50.

DBV Technologies Stock Up 0.2%

The company has a market capitalization of $953.87 million, a P/E ratio of -3.61 and a beta of -0.95. The business has a 50 day simple moving average of $17.68 and a 200-day simple moving average of $19.64.

DBV Technologies (NASDAQ:DBVT) last released its quarterly earnings data on Thursday, April 30th. The company reported ($0.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.42). The firm had revenue of $0.90 million during the quarter, compared to analyst estimates of $1.11 million. DBV Technologies had a negative return on equity of 129.88% and a negative net margin of 2,895.37%. Equities analysts forecast that DBV Technologies S.A. will post -0.38 EPS for the current fiscal year.

Hedge Funds Weigh In On DBV Technologies

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. MPM Bioimpact LLC acquired a new stake in DBV Technologies in the 2nd quarter valued at approximately $9,649,000. Adage Capital Partners GP L.L.C. bought a new position in shares of DBV Technologies in the second quarter worth $9,659,000. Octagon Capital Advisors LP bought a new position in shares of DBV Technologies in the second quarter worth $9,315,000. Two Sigma Investments LP acquired a new position in shares of DBV Technologies during the third quarter valued at $167,000. Finally, Citadel Advisors LLC acquired a new position in shares of DBV Technologies during the third quarter valued at $220,000. 71.74% of the stock is owned by institutional investors.

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.